For decades, LDL cholesterol has been the default target guiding statin therapy decisions — but a growing body of evidence suggests this single marker leaves meaningful cardiovascular risk undetected. A rigorous economic evaluation now asks not just which lipid marker is biologically superior, but whether switching clinical practice to apolipoprotein B (apoB) actually delivers better value for money at a population scale.
Using a computer simulation model built from a cohort of 250,000 statin-eligible, cardiovascular disease-free U.S. adults drawn from NHANES data (2005–2016), researchers compared the cost-effectiveness of intensifying lipid-lowering therapy — with high-intensity statins or ezetimibe — when guided by three different treatment targets: LDL-C below 100 mg/dL, non-HDL-C below 118 mg/dL, or apoB below 78 mg/dL. The apoB threshold is notably more sensitive to residual atherogenic particle burden, particularly in patients with elevated triglycerides or insulin resistance where LDL-C systematically underestimates risk. The model incorporated inputs from national survey data, pooled longitudinal cohort studies, and published clinical literature, with both traditional and probabilistic sensitivity analyses applied to stress-test results.
This analysis arrives at a clinically important inflection point. ApoB has long been endorsed by many lipidologists as the mechanistically correct target — each apoB particle represents one atherogenic lipoprotein, regardless of its cholesterol content — yet it remains underutilized globally due to cost, availability, and inertia. If this modeling confirms apoB-guided intensification is cost-effective at conventional willingness-to-pay thresholds (typically $100,000–$150,000 per quality-adjusted life year in the U.S.), it strengthens the case for guideline revision. Key limitations include the simulation's dependence on observational cohort assumptions and the challenge of modeling long-term medication adherence. This is not yet a practice-changing mandate, but for clinicians managing patients with metabolic syndrome or diabetes — where LDL-C most misleads — apoB monitoring now has both biological and economic arguments behind it.